Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.
about
Current perspectives on the immunopathogenesis of systemic sclerosisPathophysiology of systemic sclerosisTargeted Therapy in Systemic SclerosisSpotlight on tocilizumab and its potential in the treatment of systemic sclerosisImmunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys.Sustained PI3K Activation exacerbates BLM-induced Lung Fibrosis via activation of pro-inflammatory and pro-fibrotic pathways.Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.Epigenetic Regulation of Interleukin 6 by Histone Acetylation in Macrophages and Its Role in Paraquat-Induced Pulmonary Fibrosis.IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases.Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.An update on biomarker discovery and use in systemic sclerosis.A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice.An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells.Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts.Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1
P2860
Q26741264-C02FA5A4-93A6-431B-A3AD-59296202EF6CQ28072568-F6CB33C9-4CB7-46F8-B85D-A1B5C71E5854Q28072943-57F76C39-6E5C-4455-8930-EAF0E4E8BE90Q28073706-C44E5B93-F53B-4D4E-B59E-3F0446F29021Q36499879-B866B6DC-60F1-405A-BF09-AF04AC6666DBQ36682162-D2638555-5529-47B6-BE8B-5F3FBB1758D0Q37471585-DCC693F4-E97A-43E6-BF9F-628AF316EF45Q37611647-8BDF4D1D-6550-462A-A041-733D81EF6660Q37614491-798D7E76-B3E5-44F2-90C4-96966B3B50AFQ38636049-09961EA2-58FA-4518-A158-D239BDDF8831Q39450087-8285D565-1EE3-4F6F-9684-643F98A57C82Q40047502-BF57AEBE-DD16-416B-9F09-AFBAC6C8DE0EQ45920167-843004E5-546E-4EB8-9177-E4BF35972638Q49989946-67070B1D-6A49-4EBB-A079-38E3B4C6B6D4Q51250934-48E7606C-EEEB-42C9-B201-89386531752BQ53165286-25E3B3F8-CC24-42EF-A3BF-72B90186D258Q58785737-FFA8AEBC-F6DD-4A27-88E8-7CCCF4A2D95F
P2860
Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@ast
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@en
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@nl
type
label
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@ast
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@en
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@nl
prefLabel
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@ast
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@en
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@nl
P2093
P2860
P356
P1476
Targeting IL-6 by both passive ...... eomycin-induced skin fibrosis.
@en
P2093
Hadley Mouhsine
Lucille Desallais
Matthieu Montes
Maxime Fréchet
Muriel Elhai
Rojo Ratsimandresy
Yannick Allanore
P2860
P2888
P356
10.1186/AR4672
P577
2014-07-24T00:00:00Z
P5875
P6179
1013234976